TYK Medicines, Inc. has disclosed a forthcoming leadership transition and a planned board refresh.

Key changes • Non-executive director (NED) Dr. Jiang Mingyu will step down on 17 August 2026 to focus on other business commitments. His departure also ends his role as an authorised representative under Hong Kong Listing Rule 3.05. • Upon Dr. Jiang’s resignation, Chairman and CEO Dr. Wu Yusheng has been appointed as the new authorised representative, effective the same day.

Board re-election proposal At an upcoming extraordinary general meeting, shareholders will vote on re-electing seven directors for a three-year term (or until the end of the Board’s second session): 1. Executive director: Dr. Wu Yusheng 2. Non-executive directors: Dr. Li Jun, Dr. Gu Eric Hong, Mr. He Chao 3. Independent non-executive directors (INEDs): Dr. Leng Yuting, Dr. Xu Wenqing, Dr. Shen Xiuhua

Independence and remuneration • All three INED candidates have confirmed full compliance with Listing Rule 3.13 independence criteria and reported no conflicts of interest. • Proposed monthly remuneration for each INED is RMB12,000 (pre-tax). The executive and non-executive director candidates will not receive board fees.

Governance continuity Following shareholder approval, TYK Medicines will issue new service contracts or appointment letters to the re-elected directors, ensuring continuity as the company progresses into its next board term.

Current board composition As of 17 August 2026, the Board comprises one executive director (Dr. Wu Yusheng), four non-executive directors (Dr. Li Jun, Dr. Gu Eric Hong, Mr. He Chao, Dr. Zhu Xiangyang) and four independent non-executive directors (Dr. Leng Yuting, Dr. Xu Wenqing, Dr. Shen Xiuhua, Mr. Jiang Xiaolin).